Immune Enhancing Effects Of Different Ginsenosides Monomeron Peripheral Lymphocytes In Vitro In Nasopharyngeal Carcinoma Patients Treated With Radiotherapy

Objective Radiation therapy is the first choice for patients with nasopharyngeal carcinoma treatment scheme, but radiotherapy in killing tumor cells at the same time also can cause damage to the body’s immune function. Ginsenosides(ginsenosidess, GS) as the main active ingredients of Ginseng has significant immune enhancement effect. This study adopts ginsenosides monomer respectively Rg3, Rg1, Rb1 stimulate nasopharyngeal carcinoma radiotherapy patients peripheral blood lymphocyte in vitro, aimed at different ginsenosidess in vitro of peripheral blood lymphocytes in patients with nasopharyngeal carcinoma radiotherapy immune regulating effect and its mechanism. Methods Selection of nasopharyngeal carcinoma and received a total of 100 patients with radiotherapy as the research object, according to random number table method were divided into the Control group, Rg3 group, Rg1 group and Rb1 group, 25 cases in each group. After the radiotherapy, separate each group patients peripheral blood lymphocyte. According to the group to join different stimulus, the Control group, respectively, to join the final concentration of 1 mg/L, 10 mg/L, 100 mg/L of DMSO, Rg3 group to join the final concentration of 1 mg/L, 10 mg/L, 100 mg/L of ginsenosides Rg3, Rg1 groups to join the final concentration of 1 mg/L, 10 mg/L, 100 mg/L of ginsenosides Rg1, Rb1 group to join the final concentration of 1 mg/L, 10 mg/L, 100 mg/L ginsenosides Rb1. Determined by MTT method was used to detect lymphocyte proliferation and flow cytometry instrument to detect lymphocyte subgroup and membrane molecules on the surface, the indirect ELISA method was detected IgG, IgM antibody levels and Th1 / Th2 cytokines. Results(1) Ginsenosides Rg3, Rg1, Rb1 treatment nasopharyngeal carcinoma after radiotherapy in patients with peripheral blood lymphocytes of 72 h, can significantly promote the ConA and lymphocyte proliferation induced by LPS, compared with the Control group differences statistically significant(P < 0.05), and the dose was significantly increased; Rg3 effect on promoting lymphocyte proliferation was significantly superior to Rg1 groups and Rb1 group(P < 0.05); Rg1 groups there was no statistically significant difference compared with Rb1 group(P > 0.05).(2) Ginsenosides Rg3, Rg1, Rb1 treatment nasopharyngeal carcinoma after radiotherapy in patients with peripheral blood lymphocytes of 72 h, can significantly increase proportion of lymphocyte subsets CD4+, CD4+/CD8 + ratio, at the same time significantly lower percentage of CD8+, statistically significant difference compared with the Control group(P < 0.05), and the dose was significantly increased; Rg3 effect significantly better than the Rg1 groups and Rb1 group(P < 0.05); Rg1 groups there was no statistically significant difference compared with Rb1 group(P > 0.05).(3) Ginsenosides Rg3, Rg1, Rb1 treatment nasopharyngeal carcinoma after radiotherapy in patients with peripheral blood lymphocytes of 72 h, can significantly increase peripheral blood T lymphocyte surface of CD3+/ HLA-DR+ and B cell surface expression of CD19+/CD69+, statistically significant difference compared with the Control group(P < 0.05), and the dose was significantly increased; Rg3 effect significantly better than the Rg1 groups and Rb1 group(P < 0.05); Rg1 groups there was no statistically significant difference compared with Rb1 group(P > 0.05).(4) Ginsenosides Rg3, Rg1, Rb1 treatment nasopharyngeal carcinoma after radiotherapy in patients with peripheral blood lymphocytes of 72 h, can significantly promote the peripheral blood lymphocyte IgG and IgM antibody secretion, compared with the Control group differences statistically significant(P < 0.05), and the dose was significantly increased; Rg3 effect significantly better than the Rg1 groups and Rb1 group(P < 0.05); Rg1 groups there was no statistically significant difference compared with Rb1 group(P > 0.05).(5) ginsenosides Rg3, Rg1, Rb1 treatment nasopharyngeal carcinoma after radiotherapy in patients with peripheral blood lymphocytes of 72 h, can significantly increased peripheral blood lymphocyte IL-2 expression, while decreased expression of IL-6, statistically significant difference compared with the Control group(P < 0.05), and the dose was significantly increased; Rg3 effect significantly better than the Rg1 groups and Rb1 group(P < 0.05); Rg1 groups there was no statistically significant difference compared with Rb1 group(P >0.05). Conclusions Ginsenosides Rg3, Rg1, Rb1 can significantly enhance antigen of nasopharyngeal carcinoma radiotherapy patients peripheral blood lymphocyte proliferation ability, oral ability, correct the lymphocyte subsets imbalance caused by radiation therapy and Th1 / Th2 immune drift, improve the body Ig G, Ig M antibody levels, and Rg3 effect significantly better than that of Rg1 and Rb1. Prompt Rg3 ginsenosides, Rg1, Rb1 can serve as a potential immune immunosuppression caused by nasopharyngeal carcinoma radiotherapy enhancer antagonism.